Compare GE Vernova Inc (GEV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Neurocrine Biosciences Inc — how do they compare? GE Vernova Inc trades at $1,028 (market cap $263.90B), while Neurocrine Biosciences Inc trades at $159 (market cap $16.76B). The key difference: GE Vernova Inc is far larger — about 15.7× Neurocrine Biosciences Inc's market cap, and GE Vernova Inc pays a 0.2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| GEV | NBIX | |
|---|---|---|
Market Cap | $263.90B | $16.76B |
Sector | Technology | Health |
52-Week High | $1.17K | $185.50 |
52-Week Low | $547.96 | $123.10 |
Enterprise Value | $253.57B | $16.78B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $990.32, down 1.0% with bearish technical signals despite strong fundamentals. The company reported impressive Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust profitability with 23.04% net margin and 91.48% ROE. Recent news highlights GEV's $176 billion backlog and positioning in AI-driven power infrastructure demand, though valuation metrics remain elevated with P/E of 28.41 and EV/EBITDA of 84.47.
Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target, representing 28% upside. Key opportunities include AI data center power demand and nuclear energy expansion, while risks include premium valuation sensitivity and execution challenges in managing rapid growth across energy segments.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
